In many cancers, the studies of expression and mechanisms of action of IGF1 splice isoforms are only based on in vitro models (e.g., breast cancer, endometrial cancer, osteosarcoma, myelogenous leukemia, or melanoma) [14,15,16,31,68,69,106]. This evidence concerns the gene IGF1 and breast carcinoma.